Bernardo Cortese

Stories

Sirolimus-coated balloon is noninferior to drug-eluting stent at one year in TRANSFORM II

Presented TRANSFORM II at TCT 2026

For years, opening a narrowed coronary artery usually meant leaving a metal stent behind. TRANSFORM II tested a different approach: a balloon coated with sirolimus, a drug that limits scar tissue, used after the lesion is prepared and with a stent available as backup.

Updated Yesterday

Notable Quotes

TRANSFORM II shows that when a lesion is well prepared, treating it with a sirolimus-coated balloon, without leaving a permanent metal implant, gives one-year clinical outcomes comparable to a modern drug-eluting stent.

from Sirolimus-coated balloon is noninferior to drug-eluting stent at one year in TRANSFORM II · Updated Yesterday

The DCB approach is a safe and effective alternative to stents in a select population of de novo lesions.

from Sirolimus-coated balloon is noninferior to drug-eluting stent at one year in TRANSFORM II · Updated Yesterday